Journal
BLOOD
Volume 123, Issue 6, Pages 863-874Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-07-517151
Keywords
-
Categories
Funding
- Lymphoma and Leukaemia Research
- British Society of Hematology
- Bright Red
- George Walker Trust
- Wellcome Trust
- Wellcome Trust [101155/Z/13/Z] Funding Source: Wellcome Trust
- MRC [G0701897, MR/L006197/1, G0800358] Funding Source: UKRI
- Medical Research Council [G0701897, MR/L006197/1, G0800358] Funding Source: researchfish
- The Sir Jules Thorn Charitable Trust [12JTA] Funding Source: researchfish
- Wellcome Trust [101155/Z/13/Z] Funding Source: researchfish
Ask authors/readers for more resources
Constitutive heterozygous GATA2 mutation is associated with deafness, lymphedema, mononuclear cytopenias, infection, myelodysplasia (MDS), and acute myeloid leukemia. In this study, we describe a cross-sectional analysis of 24 patients and 6 relatives with 14 different frameshift or substitution mutations of GATA2. A pattern of dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency (DCML deficiency) with elevated Fms-like tyrosine kinase 3 ligand (Flt3L) was observed in all 20 patients phenotyped, including patients with Emberger syndrome, monocytopenia with Mycobacterium avium complex (MonoMAC), and MDS. Four unaffected relatives had a normal phenotype indicating that cellular deficiency may evolve over time or is incompletely penetrant, while 2 developed subclinical cytopenias or elevated Flt3L. Patients with GATA2 mutation maintained higher hemoglobin, neutrophils, and platelets and were younger than controls with acquired MDS and wild-type GATA2. Frameshift mutations were associated with earlier age of clinical presentation than substitution mutations. Elevated Flt3L, loss of bone marrow progenitors, and clonal myelopoiesis were early signs of disease evolution. Clinical progression was associated with increasingly elevated Flt3L, depletion of transitional B cells, CD56(bright) NK cells, naive T cells, and accumulation of terminally differentiated NK and CD8(+) memory T cells. These studies provide a framework for clinical and laboratory monitoring of patients with GATA2 mutation and may inform therapeutic decision-making.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available